Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AIM NASDAQ:CVKD NASDAQ:MIRA NASDAQ:THAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMAIM ImmunoTech$2.48+1.6%$5.22$2.33▼$36.00$6.72M0.9865,376 shs50,326 shsCVKDCadrenal Therapeutics$13.24+5.8%$12.01$6.89▼$22.90$27.11M0.9527,445 shs37,067 shsMIRAMIRA Pharmaceuticals$1.40+1.4%$1.47$0.73▼$2.56$26.70M1.75180,654 shs135,131 shsTHARTharimmune$3.68-7.8%$2.48$0.95▼$9.08$20.94M1.5630.98 million shs2.38 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMAIM ImmunoTech0.00%+1.35%-8.82%-72.87%-92.70%CVKDCadrenal Therapeutics0.00%+2.16%+25.14%-12.32%+63.26%MIRAMIRA Pharmaceuticals0.00%+2.19%+2.19%0.00%-17.65%THARTharimmune0.00%-38.15%+192.06%+143.72%+23.91%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMAIM ImmunoTech$2.48+1.6%$5.22$2.33▼$36.00$6.72M0.9865,376 shs50,326 shsCVKDCadrenal Therapeutics$13.24+5.8%$12.01$6.89▼$22.90$27.11M0.9527,445 shs37,067 shsMIRAMIRA Pharmaceuticals$1.40+1.4%$1.47$0.73▼$2.56$26.70M1.75180,654 shs135,131 shsTHARTharimmune$3.68-7.8%$2.48$0.95▼$9.08$20.94M1.5630.98 million shs2.38 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMAIM ImmunoTech0.00%+1.35%-8.82%-72.87%-92.70%CVKDCadrenal Therapeutics0.00%+2.16%+25.14%-12.32%+63.26%MIRAMIRA Pharmaceuticals0.00%+2.19%+2.19%0.00%-17.65%THARTharimmune0.00%-38.15%+192.06%+143.72%+23.91%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMAIM ImmunoTech 3.00Buy$275.0010,988.71% UpsideCVKDCadrenal Therapeutics 3.00Buy$32.00141.69% UpsideMIRAMIRA Pharmaceuticals 3.50Strong Buy$17.001,114.29% UpsideTHARTharimmune 3.50Strong Buy$17.00361.96% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMAIM ImmunoTech$121K55.52N/AN/A$0.20 per share12.40CVKDCadrenal TherapeuticsN/AN/AN/AN/A$4.17 per shareN/AMIRAMIRA PharmaceuticalsN/AN/AN/AN/A$0.13 per shareN/ATHARTharimmuneN/AN/AN/AN/A$0.68 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMAIM ImmunoTech-$28.96M-$24.68N/AN/AN/A-12,594.21%-421.73%-147.54%N/ACVKDCadrenal Therapeutics-$10.65M-$8.88N/AN/AN/AN/A-265.37%-196.38%11/6/2025 (Estimated)MIRAMIRA Pharmaceuticals-$7.85M-$0.49N/AN/AN/AN/A-406.70%-328.44%11/11/2025 (Estimated)THARTharimmune-$12.20M-$6.10N/A∞N/AN/A-1,239.20%-365.06%N/ALatest AIM, MIRA, THAR, and CVKD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025MIRAMIRA Pharmaceuticals-$0.11-$0.09+$0.02-$0.09N/AN/A8/14/2025Q2 2025THARTharimmune-$0.58-$0.64-$0.06-$0.64N/AN/A8/11/2025Q2 2025CVKDCadrenal Therapeutics-$1.60-$1.87-$0.27-$1.87N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMAIM ImmunoTechN/AN/AN/AN/AN/ACVKDCadrenal TherapeuticsN/AN/AN/AN/AN/AMIRAMIRA PharmaceuticalsN/AN/AN/AN/AN/ATHARTharimmuneN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMAIM ImmunoTech0.050.750.75CVKDCadrenal TherapeuticsN/A3.553.55MIRAMIRA PharmaceuticalsN/A2.802.80THARTharimmuneN/A1.171.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMAIM ImmunoTech12.02%CVKDCadrenal Therapeutics7.92%MIRAMIRA Pharmaceuticals35.16%THARTharimmune1.16%Insider OwnershipCompanyInsider OwnershipAIMAIM ImmunoTech0.02%CVKDCadrenal Therapeutics26.09%MIRAMIRA Pharmaceuticals6.65%THARTharimmune10.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMAIM ImmunoTech202.71 million68.74 millionNot OptionableCVKDCadrenal Therapeutics42.05 million1.51 millionNot OptionableMIRAMIRA Pharmaceuticals219.07 million17.80 millionNot OptionableTHARTharimmune25.69 million5.12 millionNot OptionableAIM, MIRA, THAR, and CVKD HeadlinesRecent News About These CompaniesTharimmune Achieves Nasdaq Compliance, Stabilizing Market PositionSeptember 5 at 11:51 AM | tipranks.comTharimmune Secures Nasdaq Listing with $7.05M RaiseSeptember 5 at 6:31 AM | tipranks.comTharimmune, Inc. to Present Innovative Research at Upcoming Fall Conferences in 2025September 4 at 8:30 AM | quiverquant.comQBiotech Stocks To Watch Today - August 25thAugust 28, 2025 | americanbankingnews.comTharimmune (THUR) Tumbles 20.7% on $5-Million Share SaleAugust 27, 2025 | insidermonkey.comTharimmune files to sell 2.46M shares of common stock for holdersAugust 26, 2025 | msn.comTharimmune Inc trading halted, volatility trading pauseAugust 26, 2025 | msn.comTharimmune Shares Drop After Securities Purchase AgreementAugust 26, 2025 | marketwatch.comWhy Tharimmune (THAR) Stock Exploded This WeekAugust 23, 2025 | msn.comWhy Is Tharimmune Stock (THAR) Blowing Up?August 22, 2025 | msn.comWhy Is Tharimmune Stock (THAR) Exploding Higher?August 21, 2025 | tipranks.comTharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential ...August 20, 2025 | newsobserver.comNTharimmune reports pharmacokinetic simulation results for TH104August 20, 2025 | msn.comTharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing TreatmentsAugust 20, 2025 | accessnewswire.comATharimmune secures key global patents for TH-104August 13, 2025 | msn.comTharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against ...August 13, 2025 | charlotteobserver.comCTharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized FentanylAugust 13, 2025 | accessnewswire.comATharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral ...August 6, 2025 | freep.comFNancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of DirectorsAugust 5, 2025 | accessnewswire.comATharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral Antibody DeliveryAugust 4, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesHow Did Peter Thiel-Backed Crypto Exchange Bullish's IPO Go?By Jordan Chussler | August 14, 2025Alphabet Reclaims $200 Threshold—Bull Run Reignited?By Ryan Hasson | August 12, 2025Is It Too Late to Jump on the Nuclear Bandwagon? By Jordan Chussler | August 25, 2025AI Glasses to Replace Smartphones? Meta Is Taking Aim at AppleBy Leo Miller | August 16, 2025Advanced Micro Devices' 2026 Forecasts Are Way Too LowBy Thomas Hughes | September 5, 2025AIM, MIRA, THAR, and CVKD Company DescriptionsAIM ImmunoTech NYSE:AIM$2.48 +0.04 (+1.64%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$2.50 +0.02 (+1.01%) As of 09/5/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.Cadrenal Therapeutics NASDAQ:CVKD$13.24 +0.73 (+5.84%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$13.00 -0.23 (-1.77%) As of 09/5/2025 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.MIRA Pharmaceuticals NASDAQ:MIRA$1.40 +0.02 (+1.45%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.40 +0.00 (+0.29%) As of 09/5/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.Tharimmune NASDAQ:THAR$3.68 -0.31 (-7.77%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$3.70 +0.02 (+0.43%) As of 09/5/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
